Skip to content

US · LFMDP · MEDICAL - PHARMACEUTICALS

LifeMD, Inc. (LFMDP) intrinsic value and stock valuation

$18.00as of 2026-11-21 · Mkt cap 159.97M

Data updated · price as of 2026-11-21

UndervaluedIC value is 20–50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

LifeMD, Inc. DCF and intrinsic value

InvestorsCraft values LFMDP with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from LFMDP’s statements →

LifeMD, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Pharmaceuticals New York City, NY 10001 lifemd.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$194.1M+39.1% 5y CAGRd
20112025
Net income
-$-7.11M
20112025
Free cash flow
-$-1.24M
20112025
Total equity
$23.2M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$194.1M$212.5M$152.6M$119M$92.9M
Operating income-$-7.67M-$-16.14M-$-14.49M-$-43.45M-$-54.3M
Net income-$-7.11M-$-18.88M-$-20.6M-$-45.54M-$-60.9M
EPSd-$-157.54K-$-458.25K-$-607.49K-$-1.47M-$-2.25M
Operating cash flow$8.28M$17.5M$8.82M-$-22.94M-$-33.09M
Capital expenditure-$-9.52M-$-11.54M-$-8.73M-$-12.89M-$-3.4M
Free cash flow-$-1.24M$5.98M$90K-$-35.83M-$-36.49M
Total assets$70.4M$72.5M$58.5M$25.7M$49.9M
Total debt$6.32M$25.1M$18.9M$4.13M$1.85M
Net debt-$-30.46M-$-9.9M-$-14.21M$170K-$-39.48M
Total equity$23.2M-$-4.05M$5.57M-$-7.31M$25.8M
Cash and short-term investments$36.8M$35M$33.2M$3.96M$41.3M
Income statement
20252024202320222021
Revenue$194.1M$212.5M$152.6M$119M$92.9M
Cost of revenue$39.3M$24.1M$18.9M$18.7M$18M
Gross profit$154.8M$188.4M$133.7M$100.4M$74.9M
Research and development expenses$7.35M$9.51M$6.06M$2.97M$950K
Selling, general and administrative expenses$144M$175.7M$128.2M$125.3M$122.1M
Other expenses$11.1M$19.3M$13.9M$15.5M$6.16M
Operating expenses$162.4M$204.5M$148.1M$143.8M$129.2M
Cost and expenses$201.7M$228.6M$167M$162.5M$147.2M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$1.36M$2.18M$2.6M$1.28M$3.02M
Depreciation and amortization$7.31M$9.49M$6.6M$1.09M$360K
Ebitda-$-1.52M-$-6.65M-$-8.21M-$-38.6M-$-57.94M
Operating income-$-7.67M-$-16.14M-$-14.49M-$-43.45M-$-54.3M
Total other income/expenses, net-$-2.52M-$-2.18M-$-2.92M-$-1.21M-$-7.02M
Income before tax-$-10.19M-$-18.33M-$-17.41M-$-44.66M-$-61.32M
Income tax expense$50K$400K$430K$360K$10K
Net income-$-7.11M-$-18.88M-$-20.6M-$-45.54M-$-60.9M
Weighted average shares outstanding$45.1M$41.2M$33.9M$31M$27M
Weighted average diluted shares outstanding$45.1M$41.2M$33.9M$31M$27M
Balance sheet
20252024202320222021
Cash and short-term investments$36.8M$35M$33.2M$3.96M$41.3M
Net receivables$9.31M$8.22M$5.28M$2.83M$980K
Inventory$2.77M$2.8M$2.76M$3.7M$1.62M
Total current assets$51.8M$48.7M$42.6M$11.3M$44.9M
Property, plant and equipment, net$5.27M$7.88M$1.07M$1.68M$1.99M
Goodwill and intangible assets$260K$15.9M$14.8M$12.7M$3.02M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$18.6M$23.7M$15.9M$14.4M$5M
Total assets$70.4M$72.5M$58.5M$25.7M$49.9M
Accounts payable$14.2M$16M$11.1M$10.1M$9.06M
Short-term debt$640K$8.95M$930K$3.55M$670K
Deferred revenue$10.8M$14.5M$8.83M$5.55M$1.5M
Total current liabilities$41.6M$60.3M$34.8M$31.4M$22.8M
Long-term debt$5.68M$16.2M$18M$570K$1.18M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$5.68M$16.3M$18.1M$1.6M$1.28M
Capital lease obligations$6.32M$6.77M$680K$1.33M$1.79M
Total liabilities$47.3M$76.5M$52.9M$33M$24.1M
Common stock$470K$420K$380K$320K$310K
Retained earnings-$-228.6M-$-236.25M-$-214.27M-$-190.56M-$-141.92M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$23.2M-$-4.05M$5.57M-$-7.31M$25.8M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$6.32M$25.1M$18.9M$4.13M$1.85M
Net debt-$-30.46M-$-9.9M-$-14.21M$170K-$-39.48M
Cash flow statement
20252024202320222021
Net income$15.6M-$-18.73M-$-20.6M-$-45.02M-$-61.32M
Depreciation and amortization$330K$9.49M$6.6M$3.77M$870K
Stock-based compensation$10.5M$12.2M$12.5M$13.7M$12.1M
Change in working capital-$-7.85M$12.7M$4.91M-$-1.55M$9.13M
Accounts receivable$1.15M-$-2.94M-$-2.44M-$-2.19M$20K
Inventory$300K$680K$760K-$-2.18M-$-410K
Accounts payable$3.24M$4.92M$980K$1.25M-$-890K
Net cash provided by operating activities$8.28M$17.5M$8.82M-$-22.94M-$-33.09M
Investments in property, plant and equipment-$-1.87M-$-1.49M-$-200K-$-370K-$-250K
Acquisitions, net$0.00$0.00$0.00-$-1.01M$0.00
Net cash used for investing activities$6.91M-$-11.54M-$-8.73M-$-13.91M-$-3.4M
Common stock issued$9.19M$0.00$16.2M$0.00$14M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid-$-3.11M-$-3.11M-$-3.11M-$-3.11M-$-870K
Net cash used for financing activities-$-13.41M-$-4.12M$29.1M-$-530K$68.6M
Net change in cash$1.78M$1.86M$29.2M-$-37.37M$32.2M
Cash at end of period$36.8M$35M$33.2M$3.96M$41.3M
Operating cash flow$8.28M$17.5M$8.82M-$-22.94M-$-33.09M
Capital expenditure-$-9.52M-$-11.54M-$-8.73M-$-12.89M-$-3.4M
Free cash flow-$-1.24M$5.98M$90K-$-35.83M-$-36.49M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About LifeMD, Inc.

        LifeMD, Inc. functions as a direct-to-patient telehealth enterprise, linking individuals with healthcare professionals throughout the United States for a diverse array of medical concerns. These services encompass everything from personalized concierge care to specialized fields such as men's sexual health and dermatology. The company operates a portfolio of distinct telehealth brands. ShapiroMD is dedicated to comprehensive hair loss solutions, offering virtual consultations, prescription medications, unique over-the-counter products, an FDA-approved medical device, and specialized compounded topical treatments for both male and female hair loss. RexMD provides virtual medical treatment from licensed providers for various men's health requirements. LifeMD Primary Care is a subscription-based, mobile-first platform delivering personalized virtual primary, urgent, and chronic care, integrating online consultations, prescription services, diagnostics, and imaging. Cleared focuses on customized treatments for allergy, asthma, and immunological conditions. Nava MD serves as a female-oriented tele-dermatology and skincare brand, facilitating virtual medical consultations with dermatologists and other experts. Beyond its healthcare focus, LifeMD also manages PDFSimpli, an online software-as-a-service (SaaS) platform that empowers users to create, edit, convert, sign, and share PDF documents. The company distributes its products and services directly to consumers, through e-commerce channels, and via third-party partner networks. Initially established in 1994 as Conversion Labs, Inc., the company officially rebranded to LifeMD, Inc. in February 2021. Its corporate headquarters are located in New York, New York.

        CEO
        Justin Schreiber
        Employees
        389
        Beta
        2.06

        Explore

        Frequently asked questions

        What is the intrinsic value of LifeMD, Inc. (LFMDP)?

        LifeMD, Inc. (LFMDP) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is LFMDP undervalued?

        LFMDP trades at a price of $18.00 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.